drugset / Trial / NCT00283556

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

NCT00283556

Phase 1/2 Completed 30 enrolled Kentuckiana Cancer Institute
RandomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.

Timeline

Start
2001-08
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 500 mg/m2 Intravenous
Subject Irinotecan Small molecule 600 mg/m2 Intravenous
Subject Irinotecan Small molecule 750 mg/m2 Intravenous

Indications